In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

One of In Vivo's 2024 Rising Leaders, Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company's lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.  

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity. 

Tune in to this one-off podcast feature discussing the state-of-play in the diagnostics sector, with guests from ImmunExpress, Lucid Diagnostics and ChromaCode. 

Non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics’ platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.

There is growing interest in rare neurological diseases, but barriers to efficient drug development exist. Bruce Leuchter, CEO of Neurvati Neurosciences, spoke to In Vivo about some of the hurdles in clinical-stage asset development and solutions to smooth that path. 

In this podcast, In Vivo speaks to Sara Barrington, CEO of Verici DX. During the discussion, Barrington outlines the challenges facing patients post-transplant, why current diagnostics are inadequate, and where the overall transplant market is headed, considering the rise of home dialysis and the potential future for xenotransplants.

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.